PROACT 2.0:改善临床试验中医患沟通的新型开源工具

Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian
{"title":"PROACT 2.0:改善临床试验中医患沟通的新型开源工具","authors":"Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian","doi":"10.1177/03008916241248007","DOIUrl":null,"url":null,"abstract":"The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials\",\"authors\":\"Luca Agnelli, Andrea Villa, Fouziah Butt, Matteo Duca, Alessandro Guidi, Marcello Carapezza, Michele Addante, Gaetano Lenoci, Paul O’Regan, Laura Russo, Sara Cresta, Alessandra Castano, Elisabella Ebrahem, Sara Alfieri, Akshita Patil, Louise Carter, Caroline Dive, Filippo Guglielmo De Braud, Silvia Damian\",\"doi\":\"10.1177/03008916241248007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.\",\"PeriodicalId\":23450,\"journal\":{\"name\":\"Tumori Journal\",\"volume\":\"20 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tumori Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/03008916241248007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03008916241248007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

数字医疗产品的使用正在显著改善临床实践。在此,我们将讨论 PROACT 2.0(患者对临床耐受性的意见报告 v2.0)的开发情况,这是米兰国家肿瘤研究所基金会(Fondazione IRCCS Istituto Nazionale Tumori)开发的一款新型开源移动和网络应用程序。该应用是与曼彻斯特克里斯蒂医院合作开发的,属于 UpSMART Accelerator 项目工作包 2 的一部分,涉及英国、西班牙和意大利的癌症转诊中心。PROACT 2.0 加强了癌症临床试验中患者与医疗服务提供者之间的沟通,使患者能够报告不良事件和副作用,医疗团队能够收集有价值的患者报告结果,用于治疗管理。PROACT 2.0 支持文本、音频和视频信息传送,提供了一个安全、非紧急的通信渠道,可与传统方法集成或取代传统方法。其用户友好的多语言界面为患者参与提供了新途径,并简化了后勤信息的处理。初步测试所获得的积极反馈,为今后在癌症研究和治疗中更广泛地应用提供了依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs The digital revolution in pathology: Towards a smarter approach to research and treatment The power of art and the powers of adolescents with cancer: Age-specific projects at Italian pediatric oncology centers bgicc 2024 abstracts
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1